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Abstract
Background: Ectonucleotidase dependent adenosine generation has been implicated in preconditioning related
cardioprotection against ischemia-reperfusion injury, and treatment with a soluble ectonucleotidase has been
shown to reduce myocardial infarct size (IS) when applied prior to induction of ischemia. However,
ectonucleotidase treatment according to a clinically applicable protocol, with administration only after induction of
ischemia, has not previously been evaluated. We therefore investigated if treatment with the ectonucleotidase
apyrase, according to a clinically applicable protocol, would reduce IS and microvascular obstruction (MO) in a
large animal model.
Methods: A percutaneous coronary intervention balloon was inflated in the left anterior descending artery for 40
min, in 16 anesthetized pigs (40-50 kg). The pigs were randomized to 40 min of 1 ml/min intracoronary infusion of
apyrase (10 U/ml, n = 8) or saline (0.9 mg/ml, n = 8), twenty minutes after balloon inflation. Area at risk (AAR) was
evaluated by ex vivo SPECT. IS and MO were evaluated by ex vivo MRI.
Results: No differences were observed between the apyrase group and saline group with respect to IS/AAR (75.7
± 4.2% vs 69.4 ± 5.0%, p = NS) or MO (10.7 ± 4.8% vs 11.4 ± 4.8%, p = NS), but apyrase prolonged the post-
ischemic reactive hyperemia.
Conclusion: Apyrase treatment according to a clinically applicable protocol, with administration of apyrase after
induction of ischemia, does not reduce myocardial infarct size or microvascular obstruction.
Background
Despite great advances in the treatment of ischemic
heart disease, acute myocardial infarction remains the
most common cause of death in the western world [1].
Modern therapy of acute myocardial infarction is aimed
at reperfusion of the ischemic tissue in order to reduce
myocardial infarct size (IS) and the extent of complica-
tions [2-6]. Although the final infarct size is reduced by
early reperfusion, reperfusion per se may lead to
immediate and accelerated injury beyond that which is
generated by ischemia alone, a phenomenon referred to
as “reperfusion injury” [7,8]. Myocardial ischemia may
also damage the endothelium leading to impairment of
the microvascular blood flow (microvascular
obstruction, MO). In the clinical setting, MO is com-
mon and an independent predictor of poorer clinical
outcome [9]. Consequently, there is a need for an
adjunctive cardioprotective therapy for myocardial sal-
vage beyond what reperfusion therapy alone can
provide.
A theoretical possibility is to utilize the adenosine
receptor system, which seems to represent an innate
protection system in the heart. Extracellular adenosine
is mainly generated from a two-step dephosphorylation
from adenosine triphosphate (ATP) by a family of
enzymes collectively known as ectonucleotidases. ATP is
degraded to adenosine monophosphate (AMP) by CD39,
also called apyrase or nucleoside triphosphate dipho-
sphohydrolase. AMP is converted to adenosine by
CD73, also called ecto-5’-nucleotidase [10,11], and is * Correspondence: david.erlinge@med.lu.se
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response to various injurious stimuli or ischemic insult
[12]. Although adenosine formation may be important,
the formation of adenosine from ATP and AMP is lim-
ited due to the availability of CD39 and CD73 which are
thus rate-limiting for extracellular adenosine formation
[13]. Adenosine activates adenosine receptors on a vari-
ety of cells [10], and in the heart it plays a role in regu-
lating, among other things, coronary blood flow, heart
rate, cardiac conduction and substrate metabolism [12].
Adenosine is also known to affect several of the pro-
posed reperfusion injury mechanisms, promoting preser-
vation of microvascular flow, reducing reactive oxygen
species (ROS) synthesis, stabilising cellular membranes,
restoring calcium homeostasis and modifying the
inflammatory process [14-22]. ATP, on the contrary, has
been found to have cardiotoxic effects [23].
Ectonucleotidase-dependent adenosine generation has
also been implicated in pre- and postconditioning
related cardioprotection against ischemia-reperfusion
injury [24]. The molecular mechanisms involved in pre-
conditioning are not completely understood but are
believed to involve adenosine receptor dependent activa-
tion of mitochondrial ATP-sensitive K+ (mitoKATP)
channels and protein kinase C (PKC) [24]. The exact
relationship between mitoKATP, PKC, and the end effec-
tors remains to be clarified. However, there is evidence
of cardiomyocyte modulation of sarcoplasmatic reticu-
lum Ca
2+ handling, and ATP depletion with secondary
effects on the mitochondrial permeability transition pore
(MPTP) leading to apoptosis [12,25-29]. Similarly to
preconditioning, postconditioning appears to activate
signalling pathways that involve adenosine, mitoKATP
and PKC, with subsequent effects on MPTPs. In that
respect, pre- and postconditioning seem to converge on
signalling pathways that involve adenosine and are active
primarily during reperfusion [30,31].
Moreover, inhibition of ATP degradation via targeted
gene deletion or inhibition of CD39 and CD73 has been
found to eliminate the cardioprotective effect of precon-
ditioning [32], and increase infarct size [33]. Ectonucleo-
tidase treatment with apyrase (CD39) has also been
shown to reduce myocardial infarct size (IS) when
applied prior to induction of ischemia [33].
However, apyrase treatment according to a clinically
applicable protocol, with administration only after induc-
tion of ischemia, has not previously been evaluated. We
therefore investigated if apyrase treatment, administered
after induction of ischemia, would reduce IS and MO.
Apyrase was chosen because it potentially could confer a
double benefit in simultaneously generating cardioprotec-
tive adenosine and reducing cardiotoxic ATP [23].
Methods
Experimental preparation
16 healthy domestic male and female 40-50 kg pigs were
fasted overnight with free access to water. Premedica-
tion was administered with azaperone (Stresnil Vet.,
Leo; Helsingborg, Sweden), 2 mg/kg intramuscularly, 30
minutes prior to the procedure. After induction of
anesthesia with thiopental (Pentothal, Abbott, Stock-
holm, Sweden) 5-25 mg/kg, the animals were orally
intubated with cuffed endotracheal tubes. Thereafter, a
slow infusion of 1.25 μl/ml fentanyl (Fentanyl, Pharma-
link AB, Stockholm, Sweden) in buffered glucose (25
mg/ml) was started at a rate of 1.5 ml/min and adjusted
as needed. During balanced anesthesia meprobamat
(Mebumal, DAK, Copenhagen, Denmark) and thiopental
(Pentothal, Abbott, Stockholm, Sweden), was titrated
against animal requirements with small bolus doses.
Mechanical ventilation was established with a Siemens-
Elema 900B ventilator in the volume-controlled mode,
adjusted in order to obtain normocapnia. Initial settings
were: respiratory rate of 15/min, tidal volume of 10 ml/
kg and positive end-expiratory pressure of 5 cmH2O.
The animals were ventilated with a mixture of dinitrous
oxide (70%) and oxygen (30%). The pigs were continu-
ously monitored with electrocardiogram (ECG) and
intraarterial blood pressure. Heparin (200 IU/kg) was
given intravenously at the start of the catheterization.
An 11 F introducer sheath (Onset, Cordis Co., Miami,
FL, USA) was inserted into the surgically exposed left
femoral vein. A 10.7 F Celsius Control™ catheter (Inner-
cool Therapies Inc, San Diego, CA, USA) was inserted
through the sheath and positioned in the inferior vena
cava with the tip of the catheter at the level of the dia-
phragm. Body temperature was measured with a tem-
perature probe (TYCO Healthcare Norden AB, Solna,
Sweden) placed in the distal part of the esophagus. The
catheter and the temperature probe were connected to
the Celsius Control console and the system was set to
maintain a normal pig body temperature of 38.0°C. A 6
F introducer sheath (Onset, Cordis Co. Miami, FL,
USA) was then inserted into the surgically exposed left
carotid artery upon which a 6 F JL4 Wiseguide™ (Boston
Scientific Scimed, Maple Grove, MN, USA) was inserted
into the left main coronary artery. The catheter was
used to place a 0.014-inch PT Choice™ guide wire (Bos-
ton Scientific Scimed, Maple Grove, MN, USA) into the
distal portion of the left anterior descending artery
(LAD). A 3.0 x 20 mm Ranger™ over-the-wire angio-
plasty balloon (Boston Scientific Scimed, Maple Grove,
MN, USA) was then positioned in the mid portion of
the LAD, immediately distal to the first diagonal branch.
All radiological procedures were performed in an
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Corp., Kyoto, Japan).
In a separate group of pigs (n = 14) the general set-up
of the experiment as described above, was established.
However, a 0.014-inch, 12 MHz pulsed Doppler flow
velocity transducer (Jometrics Flowire, Jomed NV, the
Netherlands) was positioned in the mid-portion of the
LAD. A 0.014-inch PT choice™ guidewire (Boston Scien-
tific Scimed, Maple Grove, MN, USA) was thereafter
inserted into the distal portion of the LAD. A 3.0 × 20
mm over-the-wire Maverick™ angioplasty balloon (Bos-
ton Scientific Scimed, Maple Grove, MN, USA) was
positioned in the mid portion of the LAD, proximal to
the flow velocity transducer but distal to the first diago-
nal branch, followed by the withdrawal of the PT choice
guidewire. Continuous coronary velocity flow profiles
were displayed and recorded using the Doppler flow
wire connected to a FloMap monitor (Cardiometrics,
Mountain View, CA, USA).
Experimental protocol
Ischemia was induced by inflation of the angioplasty bal-
loon for 40 min. An angiogram was performed after
inflation of the balloon and before deflation of the bal-
loon in order to verify total occlusion of the coronary
vessel and correct balloon positioning. After deflation of
the balloon a subsequent angiogram was performed to
verify restoration of blood flow in the previously
occluded artery. Twenty minutes after balloon inflation,
pigs were randomized to 40 min of 1 ml/min intracor-
onary infusion of the ectonucleotidase apyrase (CD39,
MDL number MFCD00130542, EC number 232-569-8,
CAS number 9000-95-7, article number A6535, lot
number 077K7016, Sigma-Aldrich, Stockholm, Sweden;
10 U/ml, n = 8) or saline (0.9 mg/ml, n = 8). According
to the specification of the manufacturer, one unit of
apyrase will liberate 1.0 μmole of inorganic phosphate
from ATP or ADP per minute at pH 6.5 at 30°C. The
infusion was made through the over-the-wire balloon,
selectively into the ischemic area.
The group of animals with flow transducers was used
in order to verify cardiac effects of the infusion of apyr-
ase. The animals in the apyrase group (n = 5) received
an intracoronary infusion of apyrase as decribed above
during a 10 minute period of ischemia, induced by infla-
tion of the balloon, whereafter reactive coronary hypere-
mia was measured and compared to controls (n = 8).
Flow was measured as average peak velocity (APV) in
cm/sec. In a closed chest pig model it is not possible to
measure vessel diameter and doppler flow simulta-
neously. However, the diameter of the LAD was mea-
sured in separate pigs from both the apyrase- and
control group during baseline and during reperfusion at
the same angle, and was found not to increase or
decrease more than 10% even during maximum reactive
hyperemia. Compensation for this only resulted in very
minor changes of the results and was therefore not
performed.
Imaging
Ex vivo imaging of the heart was undertaken according
to a previous described protocol [34,35]. The MR and
SPECT images were analyzed using freely available soft-
ware (Segment 1.700, Medviso, Lund, Sweden, http://
segment.heiberg.se) [36].
Infarct size and microvascular obstruction assessed by ex
vivo MRI
A gadolinium-based MRI contrast agent (Dotarem,
gadoteric acid, Gothia Medical, Billdal, Sweden) was
administered intravenously (0.4 mmol/kg) 30 minutes
prior to explantation of the heart. The heart was
removed 4 h after initiation of reperfusion. After
removal, the heart was immediately rinsed in cold saline
and the ventricles were filled with balloons containing
deuterated water. MRI was performed using a 1.5 T Phi-
lips Intera CV MR scanner (Philips, Best, the Nether-
lands). T1-weighted images (time resolution = 20 ms,
echo time = 3.2 ms, flip angle = 70° and 2 averages)
with an isometric resolution of 0.5 mm covering the
entire heart were then acquired using a quadrature head
coil. The endocardial and epicardial borders of the left
ventricular myocardium were manually delineated in
short-axis ex vivo images. The volume of the left ventri-
cular myocardium was calculated as the product of the
slice thickness (cm) and the area formed by the deli-
neated borders of the epi- and endocardium. The infarct
size was determined as the volume of infarcted myocar-
dium (cm
3). The infarct volume was calculated as the
product of the slice thickness (cm) and the area of
hyperenhanced pixels (cm
2) with a signal intensity above
the infarction threshold defined as > 8 SD above the
mean intensity of non-affected remote myocardium [37].
Microvascular obstruction was defined as hypointense
regions in the core of the infarction which had signal
intensity less than the threshold for infarction. These
regions were manually included in the infarct volume.
The volume of microvascular obstruction (cm
3) was cal-
culated as the difference between the infarct volume
before and after manual inclusion of regions of micro-
vascular obstruction. The size of microvascular obstruc-
tion was expressed as percent of the total infarct
volume. The infarct size was expressed as percent of left
ventricular myocardium as well as percent of the area at
risk (IS/AAR) in order to adjust for any difference in
AAR between the groups.
Ex vivo assessment of area at risk by SPECT
Single photon emission computed tomography (SPECT)
was used to assess the AAR as percent of left ventricular
myocardium. Five hundred MBq of
99 mTc-tetrofosmin
was administered intravenously ten minutes before
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performed with a dual head camera (Skylight, Philips,
Best, the Netherlands) at 64 projections (60 s per pro-
jection) with a 64 X 64 matrix and a zoom factor of
2.19, yielding a digital resolution of 4.24 X 4.24 X 4.24
mm. Iterative reconstruction using maximum likeli-
hood-expectation maximization (MLEM) was performed
with a low-resolution Butterworth filter with a cut-off
frequency set to 0.6 of Nyquist and order 5.0. No
attenuation or scatter correction was applied. Finally
short and long-axis images were reconstructed. The
endocardial and epicardial borders of the left ventricle
that were manually delineated in the MR images were
copied to the co-registered SPECT images. A SPECT
defect was defined as a region within the MRI-deter-
mined myocardium with counts lower than the 55% of
the maximum counts in the myocardium (Ugander M,
Soneson H, Heiberg E et al. A novel method for quanti-
fying myocardial perfusion SPECT defect size by co-regis-
tration and fusion with MRI - an experimental ex vivo
imaging pig heart study. Abstract. Proceedings of the
Swedish Heart Association Spring Meeting 2008).
Calculation and statistics
Calculations and statistics were performed using the
GraphPad Prism 4.0 software (GraphPad Software, Inc.,
La Jolla, CA, USA). Values are presented as mean ±
SEM. Statistical significance was accepted when P < 0.05
(Mann-Whitney’s test).
Ethics
The study conforms to the Guide for the Care and Use
of Laboratory Animals, US National Institute of Health
(NIH Publication No. 85-23, revised 1996) and was
approved by the Ethics Committee of Lund University,
Sweden.
Results
Heart rate and mean arterial pressure did not differ sig-
nificantly between the groups throughout the experi-
ment, figure 1 and 2. IS was 28.9 ± 3.1% of the left
ventricular mass in the apyrase group and 27.0 ± 3.8%
of the left ventricular mass in the saline group, p = NS
(figure 3). AAR was 37.9 ± 3.1% of the left ventricular
mass in the apyrase group and 37.8 ± 3.4% of the left
ventricular mass in the saline group, p = NS. No differ-
ences were seen between the apyrase group and saline
group with respect to IS/AAR (75.7 ± 4.2% vs 69.4 ±
5.0%, p = NS) or MO (10.7 ± 4.8% vs 11.4 ± 4.8%, p =
NS), figure 4 and 5. pH and base excess (BE) did not
differ between the groups, table 1. In the group where
coronary blood flow was measured, a pronounced post-
ischemic reactive hyperemia was observed. Infusion of
apyrase caused a statistically significant increase in the
later part of the hyperemic flow, figure 6.
Discussion
This study evaluates the cardioprotective effect of apyr-
ase treatment, according to a clinically applicable proto-
col with administration during and after ischemia. The
main findings were that IS/AAR and MO were unaf-
fected by apyrase treatment. However, reactive hypere-
mia was prolonged by apyrase.
The porcine model was chosen because it more clo-
sely resembles the human pathophysiology than the
rodent models and also allows for a closed chest model
utilising human coronary interventional devices. A per-
cutaneous catheter-based approach allows for induction
of ischemia with minimum trauma, operation-induced
stress and secondary changes in circulatory physiology.
The porcine model also offers the possibility of SPECT
and MRI for ischemia and infarct size evaluation. Ex
vivo MRI allows for acquisition of high resolution
images and objective semiautomatic quantification of
myocardial infarction, and correlates closely to histology
Table 1 Arterial blood-gas data
Saline Apyrase P-value
pH - baseline 7.50 (± 0.02) 7.49 (± 0.03) NS
pH - 15 min 7.45 (± 0.03) 7.44 (± 0.07) NS
pH - 45 min 7.44 (± 0.02) 7.42 (± 0.03) NS
pH - 75 min 7.46 (± 0.02) 7.43 (± 0.03) NS
Base excess - baseline 8.10 (± 0.52) 8.15 (± 0.78) NS
Base excess - 15 min 5.62 (± 1.14) 6.80 (± 1.90) NS
Base excess - 45 min 5.18 (± 1.00) 5.18 (± 1.86) NS
Base excess - 75 min 5.05 (± 0.79) 5.05 (± 1.7) NS
Values are expressed as mean and SEM. pH and base excess were similar
between the groups throughout the experiment. The unit for base excess is
mmol/L and for pH -log10{H
+}
Figure 1 Heart rate. Heart rate did not differ significantly between
the groups. At 90 minutes there was a trend towards a lower heart
rate in the apyrase group (112 ± 5 vs 131 ± 8, p = 0.09). Error bars
denote SEM.
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methods of evaluation of ischemia and infarct size in
clinical practice. In order to avoid a spontaneous varia-
tion in temperature during the experiment, a normal
core body temperature of pigs (38°C) was established
before induction of ischemia. A temperature difference
between the groups could thus not camouflage a true
effect of apyrase treatment. Temperature is known to be
a major determinant of infarct size [39]. The placement
of the balloon after the first diagonal branch resulted in
reproducible ischemia of, on average, 38% of the left
ventricle, with no difference in AAR between the
groups.
There was a trend towards lower heart rate in the
apyrase group that may be related to the inhibitory
effect of generated adenosine on heart rate [40]. How-
ever, there were no statistically significant differences in
hemodynamic parameters between the groups.
This trial was specifically aimed at evaluating the clini-
cal applicability of apyrase treatment in the setting of
ST-segment elevation myocardial infarction (STEMI).
The prehospital patient delay time is often significantly
longer than the in-hospital door-to-reperfusion time and
the window of opportunity for cardioprotective treat-
ment is thus limited to the later part of ischemia [41].
Consequently, apyrase was administered only during the
final 20 minutes of ischemia and continued after reper-
fusion, in order to mimic the clinical situation. The total
ischemia time of 40 min is shorter than in the typical
patient with myocardial infarction, which typically
experience 2-4 hours of ischemia before start of treat-
ment. However, pigs complete myocardial infarction
more rapidly than humans, and longer duration of
ischemia have resulted in a large established infarct
before initiation of apyrase treatment [42].
Previously, apyrase treatment has been shown to
reduce IS/AAR with 43% when administered 30 minutes
prior to a period of 60 minutes of ischemia in a rodent
model [33]. In that study, 80 U/kg of apyrase was admi-
nistered in wild-type mice. With an average mouse
weight of 20 g and a percentage distribution of cardiac
output with 18% going to the heart during rest [43],
0.28 U of apyrase would have been delivered to the
heart. In our study, an approximately 1400 times higher
dose of 400 U was infused directly into the ischemic
area in order to maximize the possible cardioprotective
effect of apyrase treatment at this later timepoint. The
finding of prolonged coronary reactive hyperemia
induced by apyrase-infusion, suggest that adenosine is
generated by the apyrase-infusion. The mechanism
behind reactive hyperemia is thought to be multifactor-
ial, but adenosine has been shown to mediate the later
phase of hyperemic flow via A2A receptors on smooth
muscle cells [44,45]. Thus, an increased level of adeno-
sine would be expected to increase the later phase of
hyperemia, which it did in our experiment. This obser-
vation is also consistent with findings of an accelerated
recovery of microvascular circulation after intracoronary
infusion of adenosine as an adjunct to primary PCI [46].
The lack of cardioprotective effect of the apyrase-infu-
sion could be explained by species-related differences in
the pharmacology of adenosine receptors. It is also pos-
sible that apyrase was not able to generate enough ade-
nosine to activate signalling via the A2B receptor, which
otherwise has been able to yield cardioprotection when
stimulated prior to reperfusion by the receptor agonist
AMP 579 in a porcine model [47]. Indeed, the A2B
receptor is known to be of lower affinity for adenosine
than the A2A receptor [48], which seemed to respond
with the increased flow seen at the end of reactive
hyperemia in the apyrase group [44,45]. However, there
is also evidence of A2A mediated cardioprotection
against ischemia-reperfusion injury [12]. Theoretically,
the high dose of apyrase that was used could also have a
cardiotoxic effect. However, we are not aware of any
such evidence in the literature. The lack of effect could
also be explained by a species-related imbalance
between apyrase and downstream adenosine generation
by CD73 as well as by a low release of native ATP and
AMP. A relative deficiency of AMP degradation capacity
would be in agreement with the uncertain effect of post-
conditioning in pigs. Two studies of postconditioning in
pig have been carried out where one was negative and
the other was negative in one arm with 4 cycles of
ischemia/reperfusion and positive in another arm with 8
cycles [49,50]. In another study in a porcine model, pre-
conditioning was found to be cardioprotective [51]. In
that study, cardiac adenosine levels were measured in
the preconditioning group and found to be increased
Figure 2 Mean arterial pressure. Mean arterial pressure did not
differ significantly between the groups. Error bars denote SEM.
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the apyrase group. White areas (arrow) are infarcted. Infarct size was similar between the groups.
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In the control group, the adenosine concentration was
elevated during ischemia, as opposed to the finding in
the preconditioning group [51]. The increased adenosine
level during ischemia seen in the control group is in
agreement with the experimental protocol in our study.
This clearly supports the conclusion that the apyrase
infusion must be initiated prior to the induction of
ischemia in order to generate a cardioprotective effect.
Thus, it is possible that apyrase treatment could prove
to be cardioprotective if initiated earlier than in the cur-
rent study, but it would be of little interest in clinical
practice. These findings may also imply that other
triggers of pre- and postconditioning, such as bradyki-
nin, opioids, nitric oxide and reactive oxygen species
[30,31,52], could be of greater importance than adeno-
sine in the setting of pre- and postconditioning. Further-
more, these factors may explain why apyrase infusion
has been found to reduce infarct size in a rodent model
but not in our porcine model.
It may be of interest to study whether or not apyrase
treatment is cardioprotective in the setting of non-ST
elevation acute coronary syndrome, where ischemia may
be less sudden in onset and time to coronary interven-
tion longer. In this less sudden setting the stimulatory
effect of adenosine on angiogenesis may prove to be
effective in tissue protection, in addition to the above
mentioned mechanisms of effect [53]. Further research
is warranted and the CD39 knockout pig under develop-
ment may be used to further advance the knowledge in
the field.
Limitations
Histopathological evaluation was not performed. MRI
correlates excellent with histological evaluation and this
would not affect the outcome parameters. However, his-
tology could have added information about changes at
the cellular and molecular levels which could be early
indicators of possible beneficial effects of apyrase. More-
over, levels of adenosine and apyrase were not mea-
sured, in part because the protocol was maximized
regarding intracoronary apyrase administration. A biolo-
gically relevant effect of the apyrase infusion was instead
confirmed by the finding of an increased reactive hyper-
emia. However, information about the amount of adeno-
sine that was generated could have conferred additional
valuable information.
Figure 4 Infarct size. Infarct size as a percentage of area at risk
from the animals in the saline group and apyrase group,
respectively. No differences were seen between the groups with
respect to IS/AAR. Horizontal line denotes mean.
Figure 5 Microvascular obstruction. Microvascular obstruction as
a percentage of infarct size from the animals in the saline group
and apyrase group, respectively. No differences were seen between
the groups with respect to MO. One animal is missing in the
apyrase group due to technical difficulties. Horizontal line denotes
mean.
Figure 6 Reactive hyperemia. Post ischemic coronary reactive
hyperemia was increased during the later phase by infusion of
apyrase (p < 0.05, time-points marked by the bracket). Error bars
denote SEM.
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In summary, apyrase treatment according to a clinically
applicable protocol, with administration of apyrase only
after induction of ischemia, does not reduce myocardial
infarct size or microvascular o b s t r u c t i o ni nt h es e t t i n g
of STEMI.
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